Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Oscillating devices vs PEP

Participant‐reported satisfaction with treatment intervention · adults and children with cystic fibrosis

1 finding from 1 review

Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 242 participants
Very low

Oscillating devices vs breathing techniques

FEV1 · adults and children with cystic fibrosis

1 finding from 1 review

Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 210 participants
Low

Oscillating devices vs breathing techniques

FEF25-75 · adults and children with cystic fibrosis

1 finding from 1 review

Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 29 participants
Very low

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Lung function(FEV1 or FVC L/min or % predicted) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Time to next exacerbation · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

1 finding from 1 review

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 82 participants
Moderate

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Quality of life · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Length of hospital stay · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Sputum bacterial density (CFU/mL) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Adverse events · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

All‐cause mortality · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: β‐carotene vs placebo

Number of days on antibiotics for acute exacerbations · adults and children with cystic fibrosis

Summary of findings: β‐carotene showed no clear difference in pulmonary exacerbations Days of antibiotic use compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Summary of findings: garlic supplementation vs placebo

Adverse events mild adverse events · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Moderate

Summary of findings: garlic supplementation vs placebo

Need for antibiotics days of antibiotic use · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: garlic supplementation vs placebo

QoL · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: garlic supplementation vs placebo

Sputum microbiology · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: garlic supplementation vs placebo

Inflammatory markers · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: monoclonal antibody KB001‐A vs placebo

Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.4]
2 studies · 196 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 4.74 [0.28, 79.44]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 1.3 [0.9, 1.87]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
HR 1 [0.69, 1.45]
1 study · 169 participants
Moderate